Shares of Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $8.51.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Homology Medicines in a report on Thursday.
Homology Medicines Stock Performance
Shares of NASDAQ:FIXX opened at $0.95 on Thursday. The firm has a market cap of $54.80 million, a PE ratio of -8.64 and a beta of -0.01. The firm’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $1.54. Homology Medicines has a one year low of $0.95 and a one year high of $3.57.
Institutional Trading of Homology Medicines
About Homology Medicines
Homology Medicines, Inc is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.
- Get a free copy of the StockNews.com research report on Homology Medicines (FIXX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.